INDYGO: intraoperative PDT for newly diagnosed GBM, 2-years follow-up (Conference Presentation)

Maximilien Vermandel; Clément Dupont; Fabienne Lecomte; Pascal Deleporte; Serge R. Mordon; Nicolas Reyns

doi:10.1117/12.2524973

14 August 2019 INDYGO: intraoperative PDT for newly diagnosed GBM, 2-years follow-up (Conference Presentation)

Maximilien Vermandel, Clément Dupont, Fabienne Lecomte, Pascal Deleporte, Serge R. Mordon, Nicolas Reyns

Proceedings Volume 11070, 17th International Photodynamic Association World Congress; 110701G (2019) https://doi.org/10.1117/12.2524973
Event: 17th International Photodynamic Association World Congress, 2019, Cambridge, Massachusetts, United States

Abstract

Background and Objective Glioblastoma (GBM) is a malignant brain tumor with a median overall survival of approximately 15 months with the current standard of care (SOC). Although it is a rare neoplastic disease with low prevalence (0.3/10,000 persons), it remains the most frequent primary malignant brain tumor in adults. Currently, there is still no therapeutic option to prevent GBM recurrence and total resection is rarely feasible because of tumor cells infiltrating the surrounding brain. Thus, adjuvant therapies to improve local control are highly expected. 5-ALA photodynamic therapies have been reported with promising results. We present here an ongoing clinical trial (INDYGO) to evaluate 5-ALA PDT delivered intraoperatively to treat newly diagnosed GBM. Materials and Methods Our group has introduced a specific light applicator to deliver PDT in the surgical cavity early after maximal resection. 5-ALA PDT is delivered in combination with the SOC recommended by the current guidelines and enabling to simultaneously investigate the potential synergistic effects. Results and Discussion Between May 2017 and June 2018 ten patients have been enrolled. Currently, therapy has been delivered without significant toxicity or adverse event and are fulfilling the primary endpoint of this feasibility study. Secondary endpoints still being under investigation are progression-free survival, overall survival and patients' quality of life. Conclusions Finally, after the feasibility and the absence of adverse effects, multicentric, parallel-group, randomized controlled trial (RCT) is planned to assess the efficacy of 5-ALA PDT for the treatment of newly diagnosed GBM.

Conference Presentation

Citation Download Citation

Maximilien Vermandel, Clément Dupont, Fabienne Lecomte, Pascal Deleporte, Serge R. Mordon, and Nicolas Reyns "INDYGO: intraoperative PDT for newly diagnosed GBM, 2-years follow-up (Conference Presentation)", Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 110701G (14 August 2019); https://doi.org/10.1117/12.2524973

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
PRESENTATION

WATCH
PRESENTATION SAVE TO MY LIBRARY

GET CITATION

KEYWORDS

Photodynamic therapy

Brain

Tumors

System on a chip

Therapeutics

Clinical trials

Toxicity

Keywords/Phrases

Search In:

Publication Years